NRG/RTOG 1112: Randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC) Meeting Abstract
| Authors: | Dawson, L. A.; Winter, K. A.; Knox, J. J.; Zhu, A. X.; Krishnan, S.; Guha, C.; Kachnic, L. A.; Gillin, M.; Hong, T. S.; Craig, T.; Hosni, A.; Chen, E. X.; Noonan, A. M.; Koay, E. J.; Sinha, R.; Lock, M.; Ohri, N.; Dorth, J. A.; Moughan, J.; Crane, C. H. |
| Abstract Title: | NRG/RTOG 1112: Randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC) |
| Meeting Title: | 2023 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2023 Jan 19-21 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-02-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.4_suppl.489 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 489 -- Accession Number: 161484946 -- Entry Date: In Process -- Revision Date: 20230127 -- Publication Type: Article -- Supplement Title: 2/1/2023 Supplement 1 -- Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA -- NLM UID: 8309333. -- Source: Cinahl |
